(Q34546599)

2 August 2017

1 reference

title

Interferon for acute hepatitis C. (English)

1 reference

2 August 2017

1

T Poynard

1 reference

2 August 2017

C Regimbeau

2

1 reference

2 August 2017

R P Myers

3

1 reference

2 August 2017

T Thevenot

4

1 reference

2 August 2017

V Leroy

5

1 reference

2 August 2017

P Mathurin

6

1 reference

2 August 2017

P Opolon

7

1 reference

2 August 2017

J P Zarski

8

1 reference

2 August 2017

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

2 August 2017

published in

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

CD000369

1 reference

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Interferon as treatment for acute hepatitis C. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Hepatitis C virus viremia following clinical resolution of acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Interferon therapy for acute hepatitis C viral infection--a review by meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Treatment of acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Interferon for non-A, non-B chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000369

Interferon alfa in acute posttransfusion hepatitis C: a randomized, controlled trial

21 January 2018

1 reference

12 December 2020

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

12 December 2020

A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.

1 reference

12 December 2020

Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial

1 reference

12 December 2020

Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response

1 reference

12 December 2020

[Evaluation of the methodological quality of randomized therapeutic trials]

1 reference

12 December 2020

Natural history of hepatitis C

1 reference

12 December 2020

The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha

1 reference

12 December 2020

Treatment of posttransfusion non-A, non-B acute and chronic hepatitis with human fibroblast beta-interferon: a preliminary report

1 reference

12 December 2020

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

12 December 2020

Interferon therapy for acute hepatitis C; changes in serum markers associated with HCV and clinical effects

1 reference

12 December 2020

1 reference

12 December 2020

A report on therapy of interferon-A2b in patients with acute hepatitis C

1 reference

12 December 2020

Interferon therapy for acute posttransfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status

1 reference

12 December 2020

Natural beta interferon in acute type-C hepatitis patients: a randomized controlled trial

1 reference

12 December 2020

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

12 December 2020

10.1002/14651858.CD000369

Identifiers

DOI

1 reference

release_u5byyixwfnfhlj6p7lww3q4lwi

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u5byyixwfnfhlj6p7lww3q4lwi

24 November 2022

mapped directly with Wikidata item

PMC publication ID

7061490

0 references

1 reference